Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Bought by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC increased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 29.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 784,376 shares of the biopharmaceutical company's stock after purchasing an additional 179,058 shares during the quarter. Parkman Healthcare Partners LLC owned 0.26% of Amicus Therapeutics worth $7,389,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the business. Nuveen Asset Management LLC grew its position in shares of Amicus Therapeutics by 4.4% in the fourth quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company's stock valued at $35,866,000 after purchasing an additional 159,139 shares during the last quarter. Orbimed Advisors LLC lifted its stake in shares of Amicus Therapeutics by 300.7% during the 4th quarter. Orbimed Advisors LLC now owns 2,285,400 shares of the biopharmaceutical company's stock worth $21,528,000 after purchasing an additional 1,715,100 shares during the period. Millennium Management LLC boosted its position in shares of Amicus Therapeutics by 10.8% in the fourth quarter. Millennium Management LLC now owns 457,014 shares of the biopharmaceutical company's stock worth $4,305,000 after acquiring an additional 44,449 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Amicus Therapeutics by 10.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 258,149 shares of the biopharmaceutical company's stock worth $2,432,000 after purchasing an additional 24,316 shares during the period. Finally, Hudson Bay Capital Management LP boosted its stake in shares of Amicus Therapeutics by 26.7% in the fourth quarter. Hudson Bay Capital Management LP now owns 1,804,800 shares of the biopharmaceutical company's stock valued at $17,001,000 after purchasing an additional 379,800 shares during the period.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. The Goldman Sachs Group dropped their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. UBS Group lifted their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Cantor Fitzgerald reiterated an "overweight" rating and set a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Finally, Wells Fargo & Company reduced their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Amicus Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $16.22.

Amicus Therapeutics Stock Down 3.1%

Shares of Amicus Therapeutics stock opened at $6.02 on Wednesday. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of -33.44, a PEG ratio of 1.51 and a beta of 0.64. The stock's 50-day moving average is $7.53 and its 200 day moving average is $9.01. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a one year low of $5.82 and a one year high of $12.65.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.